Shivangi Agarwal

Shivangi Agarwal

Auto-generated profile, based on publicly available information

Shivangi Agarwal

Grove Biopharma Inc 1375 W. Fulton St., Ste. 650 Chicago 60558 IL USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
SMSUMIT KUMAR MATTA
SUMIT KUMAR MATTA
SAShivangi Agarwal
Shivangi Agarwal
RBRakesh Bhatnagar
Rakesh Bhatnagar

16 February 2024 in Advanced Materials
Verified
Journal Article
Open access
KCKendal P. Carrow
Kendal P. Carrow
HHHaylee L. Hamilton
Haylee L. Hamilton
MHMadeline P. Hopps
Madeline P. Hopps
YLYang Li
Yang Li
BQBaofu Qiao
Baofu Qiao
NGNathan C. Gianneschi
Nathan C. Gianneschi
Successful and selective inhibition of the cytosolic protein‐protein interaction (PPI) between nuclear factor erythroid 2‐related factor 2 (Nrf2) and Kelch‐like ECH‐associating protein 1 (Keap1) can enhance the antioxidant response, with the potential for a therapeutic effect in a range of settings including in neurodegenerative disease (ND). Small molecule inhibitors have been developed, yet many have off‐target effects, or are otherwise limited by poor cellular permeability. Peptide‐based strategies have also been attempted to enhance specificity, yet face challenges due to susceptibility to degradation and lack of cellular penetration. Herein, these barriers are overcome utilizing a polymer‐based proteomimetics. The protein‐like polymer (PLP) consists of a synthetic, lipophilic polymer backbone displaying water soluble Keap1‐binding peptides on each monomer unit forming a brush polymer architecture. The PLPs are capable of engaging Keap1 and displacing the cellular protective transcription factor Nrf2, which then translocates to the nucleus, activating the antioxidant response element (ARE). PLPs exhibit increased Keap1 binding affinity by several orders of magnitude compared to free peptides, maintain serum stability, are cell‐penetrant, and selectively activate the ARE pathway in cells, including in primary cortical neuronal cultures. Keap1/Nrf2‐inhibitory PLPs have the potential to impact the treatment of disease states associated with dysregulation of oxidative stress, such as NDs.

2 June 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
ARAmit Rahi
Amit Rahi
MCManas Chakraborty
Manas Chakraborty
SAShivangi Agarwal
Shivangi Agarwal
KVKristen M. Vosberg
Kristen M. Vosberg
AWAnnie Y. Wang
Annie Y. Wang
DVDileep Varma
Dileep Varma
It is known that microtubule-binding proteins including the Ska1 complex and the DNA replication licensing factor, Cdt1, enable the kinetochore-localized Ndc80 complex to form robust kinetochore-microtubule attachments. However, it is not clear how the Ndc80 complex is stably coupled to dynamic spindle microtubule plus-ends. Here, we have developed a conditional auxin-inducible degron approach to reveal a function for Cdt1 in chromosome segregation and kinetochore–microtubule interactions that is separable from its role in DNA replication licensing. Further, we demonstrate that a direct interaction between Cdt1 and Ska1 is required for recruiting Cdt1 to kinetochores and spindle microtubules. Cdt1 phosphorylation by Cdk1 kinase is critical for Ska1 binding, kinetochore–microtubule attachments, and mitotic progression. Furthermore, we show that Cdt1 synergizes with Ndc80 and Ska1 for microtubule binding, including forming a diffusive, tripartite Ndc80-Cdt1-Ska1 complex that can processively track dynamic microtubule plus-ends in vitro. Taken together, our data identify the Ndc80-Cdt1-Ska1 complex as a central molecular unit that can promote processive bidirectional tip-tracking of microtubules by kinetochores.